Mission Statement

Firmly grounded in nearly a decade of discovery research, prior to its founding, NOX Technologies Inc. has the potential to develop the first universal test for early detection of most if not all forms of human cancer from serum or urine samples. The test utilizes cancer-specific isoforms to a single protein marker, tNOX that initially will help oncologists monitor therapy and detect and diagnose the cancers sooner. The immediate goal is a tNOX-based monoclonal antibody array that will not only detect cancer early (Stage I) but discriminate among 30+ major forms of human cancer. Also envisioned is deployment of the cancer specific tNOX protein as an immunotherapeutic and chemotherapeutic target.